Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
REVENUES:    
Product revenue $ 4,006,298 $ 2,593,163
License and other revenue 35,708 35,708
Total Revenues 4,042,006 2,628,871
OPERATING EXPENSES    
Cost of product revenue (exclusive of amortization expense shown below) 12,242,748 1,616,287
Research and development 1,281,706 1,192,727
Plasma centers 1,833,774 1,479,476
Amortization of intangibles 211,235 0
Selling, general and administrative 5,005,046 4,277,384
TOTAL OPERATING EXPENSES 20,574,509 8,565,874
LOSS FROM OPERATIONS (16,532,503) (5,937,003)
OTHER INCOME (EXPENSE):    
Interest income 26,546 18,568
Interest expense (1,323,152) (618,528)
Other income 6,967 0
OTHER EXPENSE, NET (1,289,639) (599,960)
NET LOSS $ (17,822,142) $ (6,536,963)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.39) $ (0.51)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 45,317,042 12,886,741